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ASSESSMENT PROCEDURES
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ABSTRACT
Purpose: The construct validity, test–retest reliability, and measurement error of the Arm Function in
Multiple Sclerosis Questionnaire (AMSQ) were examined. Additionally, the influence of administration-
method on reliability and measurement error was investigated.
Method: 112 Dutch adult MS-patients from an academic- and a residential care-facility participated.
Questionnaires were administered on paper, online or as interview, and patients performed several per-
formance tests. Construct validity was assessed by testing pre-defined hypotheses. Reliability was assessed
using Intraclass Correlation Coefficients (ICCs), Standard Error of Measurements (SEMs) and Smallest
Detectable Changes (SDCs).
Results: For construct validity (N¼ 105) 9 of 13 hypotheses were confirmed (69%). As expected, the
AMSQ showed moderate to strong relationships with the instruments measuring similar constructs. The
test–retest reliability coefficient was 0.96 (95% Confidence Interval 0.94–0.97); SEM was 6.3 (6.3% of scale
range); SDC was 17.5 (on a sale from 0 to 100). Different administration-methods showed good reliability
(ICC 0.88–0.94) and small standard errors (SEM 5.6–7.2).
Conclusion: The AMSQ shows satisfying results for validity and excellent reliability; allowing for proper
use in research. Due to a large SDC value, caution is needed when using the AMSQ in individual patient
care. Further research should determine whether the SDC is smaller than the minimal important change.
 IMPLICATIONS FOR REHABILITATION
 The Arm Function in Multiple Sclerosis Questionnaire (AMSQ) measures activity limitations due to
hand and arm functioning in patients with Multiple Sclerosis (MS).
 Results of this study confirm adequate validity and reliability of the AMSQ in patient with MS.
 The equivalence of scores from online, paper or interview administration is supported.
 A change score of 18 points on the scale of the AMSQ (on a scale 0–100) needs to occur to be cer-
tain a change beyond measurement error has occurred in an individual patient.
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Introduction
Multiple Sclerosis (MS) is a progressive disease and is highly asso-
ciated with increased physical disability. Limitations in hand and
arm functioning are present in up to 76% of patients [1–4] includ-
ing patients with low disease severity.[3] Impairments may include
tremor, coordination deficit and muscle weakness.[5] Limitations
in hand and arm function have significant negative implications
on activities of daily living (ADL) (e.g., eating, dressing, groom-
ing),[6] living independently, and quality of life (QoL),[7–9] and are
associated with high societal costs due to loss of work and high
direct costs due to utilization of care.[10] Given their impact, valid
assessment of hand and arm functioning is important in both clin-
ical practice and clinical trials, i.e., for the comprehensive
evaluation of therapeutic effectiveness and in the development of
treatment strategies.[11,12]
Patient Reported Outcome Measures (PROMs) capture the
patient’s perspective of a person’s health condition and are
advised when measuring functioning.[13,14] Moreover, along with
the recognition of the importance of patient-centered care,
PROMs have gained increased importance in the assessment of
MS. There are several PROMs for measuring upper extremity func-
tion.[15–19] However, no unidimensional disease specific PROM is
available for measuring arm and hand functioning in persons with
MS. Therefore, the Arm Function in Multiple Sclerosis
Questionnaire (AMSQ) was recently developed [20] to measure
activity limitations due to hand and arm functioning in patients
with MS. The term “activity limitations” was defined according to
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the International Classification of Functioning, Disability and
Health (ICF) as any difficulties an individual may have in execut-
ing activities.[21] The AMSQ was based on a literature review
and with involvement of experts and patients, and using item
response theory (IRT) methods.[20] More details are published
elsewhere.[20] In total, 31 items were included in the question-
naire constituting a unidimensional scale. All items are formu-
lated as “during the past two weeks, to what extent has MS
limited your ability to…”. Response categories are not at all, a
little, moderately, quite a lot, extremely, and no longer able to.
The aim is to develop a computer adaptive test in the future,
requiring an item bank containing a sufficient number of items
that cover the range of activity limitations due to hand and
arm functioning for patients with MS. In the present study, we
further investigated the quality of the AMSQ using classical test
theory (CTT) methods. The aim of this study was to investigate
construct validity, test–retest reliability, and measurement error.
Often in research, different modes of administration are used,
such as self-report, or interview. Moreover, a self-report version
can either be administered at the clinic or at home, by paper
and pencil or online. In general, different ways of administration
can influence the scores. Therefore, we subsequently investi-
gated whether the mode of administration influenced the reli-
ability and measurement error of the AMSQ.
Method
Study design and patients
In this test–retest design, a prospective cohort of patients with MS
was recruited at the VU University Medical Center (VUmc) in
Amsterdam and the residential and facility center for physically
handicapped, Nieuw Unicum (NU) in Zandvoort, both in the
Netherlands. A sample of patients was enrolled at the VUmc at
regular patient visits at the outpatient clinic or in the context of
clinical ongoing research projects. In addition, patients were
recruited from advertisements on Dutch websites, i.e., www.
msweb.nl and www.msvamsterdam.nl. Patients at NU were
recruited by the staff of the center. Inclusion criteria were: self-
indicated diagnosis of any type of MS, age above 18 years, and
adequate understanding of the Dutch language. Patients with clin-
ically observable severe cognitive impairments were excluded. The
study was approved by the Medical Ethical Committee of the VU
University Medical Center, Amsterdam; the Netherlands (reference
number 2012/296). Data collection was carried out between
November 2012 and June 2013.
Procedures
Patients were examined at VUmc or at NU. All patients were asked
to sign an informed consent form, and to complete a question-
naire, containing demographic variables and disease specific
questions (i.e., age, gender, disease duration, and MS type), a self-
administered version of the Expanded Disability Status Scale
(EDSS),[22] and several other PROMS including the AMSQ (see
below) provided online or on paper. Furthermore, all patients were
interviewed to assess level of disability due to MS (i.e., The Guy’s
Neurological Disability Scale, see below) and were asked to perform
several performance tests (see below). At NU, the questionnaires
were administered as interview, as most patients were unable to fill
out the questionnaires themselves due to hand and arm impair-
ments. At VUmc, patients self-administered the questionnaires.
After two to four weeks we asked patients again to complete
the AMSQ, assuming that this time interval was sufficient to
minimize recall bias, yet short enough for their hand and arm
function to remain unchanged. To check whether patients were
stable in the meantime, a Global Perceived Effect (GPE) scale
about perceived changes in hand and arm functioning was
administered (see below).
Measurements
Patient reported outcome measures
 The AMSQ measures activity limitations due to hand and
arm function in patients with MS. All items fitted into the
graded response model, which is an IRT model, and no
differential item functioning (DIF) was found for the varia-
bles type of MS, gender, administration version, and test
length. IRT based reliability was 0.95.[20] The items of the
AMSQ are provided in Appendix 1. As this study is based
on CTT, we calculated sum scores (range 0–100) instead of
IRT-based trait level (h) scores. Higher scores indicate more
limitations in hand and arm function. No scores were
imputed, only complete cases were used.
 The Guy’s Neurological Disability Scale (GNDS) is an struc-
tured interview assessing level of disability (i.e., activity
limitations).[23,24] The GNDS contains 12 functional
domains, but we used only the total GNDS score (range
0–60) and the upper limb disability sub score (range 0–5).
Each domain contains four to ten dichotomous items.
Based on the given answers, domain scores are ascribed
on a six-point severity scale, e.g., the upper limb disability
scoring ranges from no upper limb problem (score ¼ 0) to
unable to use either arm for any purposeful movements
(score ¼ 5). No missing variables were expected, as the
scale was administered as interview.
 The RAND-36 is a license free version of the Short-Form
Health Survey-36 (SF-36),[25,26] and comprises 36 items
assigned to eight scales: physical functioning (10 items),
role-physical (4 items), bodily pain (2 items) and general
health (5 items), vitality (4 items), social functioning (2
items), role-emotional (3 items) and mental health (5
items). The scores of each domain were transformed so
that a higher score indicates better health status (range
0–100).
 The Multiple Sclerosis Impact Scale-29 (MSIS-29) measures
the impact of MS on daily living, comprising a physical
impact scale (MSIS-29 physical) and a psychological impact
scale (MSIS-29 psychological).[27,28] All items have a five-
point Likert scale ranging from not at all to extremely, with
higher scores indicating higher impact (range physical
subscale 20–100; range psychological subscale 9–45).
 The Multiple Sclerosis Impact Profile (MSIP) measures disabil-
ity in patients with MS. Only the subscale measuring activ-
ities of daily living was utilized.[29] Answering is on a
four-point scale, ascending in degree of need for support-
ing tools and/or help from others, i.e., higher scores indi-
cated more dependence (range 7–28).
 GPE scale.[30] At follow-up patients were asked How would
you rate your hand/arm functioning, compared to two
weeks ago?. Response options were: (1) much better than
two weeks ago, (2) somewhat better than two weeks ago,
(3) about the same as two weeks ago, (4) somewhat worse
than two weeks ago, and (5) much worse than two weeks
ago. Patients who reported much better or much worse on
the GPE scale were regarded as unstable patients and
were excluded from reliability analyses.
2098 L. M. V. LEEUWEN ET AL.
Missing items on the RAND-36, MSIS-29 and MSIP were
imputed as recommended with patient-specific mean values of
completed items.
Performance tests
All administered performance-based tests are designed to meas-
ure each hand or arm independently. Scores were obtained for
both hands/arms. Because the AMSQ was designed regardless of
hand-dominance, we averaged the scores of the dominant and
non-dominant hand for each performance based test.
 The Action Research Arm test (ARAT) was used to measure
fine and gross motor dexterity.[31] The test consists of five
subtests: grasp (6 items), grip (4 items), pinch gross (4
items), pinch fine (4 items), and gross movement (3 items),
comprising a total of 19 movements to be performed by
the patient. Each movement is scored on a scale from no
movement possible (score ¼ 0) to normal movement (score
¼ 3) (range 0–57).
 The Nine Hole Peg Test (9-HPT) was used to measure upper
extremity function,[32] and involves placing and removing
nine pegs in a pegboard. The time to perform the test
was measured.
 The Coin Rotation Task (CRT) was used to measure fine
motor dexterity of the hands,[33] and involves rotating a
US five-cent coin as fast as possible using the thumb,
index and middle fingers. The time to perform 20 half-
turns was measured.
 The hand held JAMAR dynamometer was used to measure
isometric grip strength of the hand.[34] The test was per-
formed following standardized instructions and positioning
recommended by the American Society of Hand
Therapists.[35]
 The Modified Ashworth Scale (MAS) was used for
measuring muscle spasticity,[36] by measuring resistance
to passive movement about the elbow joint on a 6-point
scale from no increase in tone to limb rigid in flexion
or extension (range 0–5). MAS scores were
dichotomized into no spasticity (i.e., MAS ¼ 0) and spasti-
city (i.e., MAS  1).
Except for the ARA test and MAS, all performance tests were
administered twice on both hands and the best value was taken
as score for each hand. If a patient could not perform a timed-test
due to hand and arm impairments, a maximum value of
300 seconds was used (according to the manual of the NHPT and
used for other tests [37]).
Statistical analyses
We produced descriptive statistics (means, medians, and SDs) for
the scores of the measurements, and investigated the frequencies
of missing data.
Construct validity
Construct validity was assessed by the degree to which the
sum scores of the AMSQ were consistent with predefined
hypotheses regarding relationships between the AMSQ and the
other measures. We formulated 13 hypotheses presented in
Table 1. Moderate to high correlations are expected between
the AMSQ and other PROMs measuring physical functioning
(hypotheses 1–6). Low correlations are expected between the
AMSQ and other PROMs measuring different constructs (hypoth-
eses 7, 8). Moderate to high correlations are expected between
the AMSQ and all performance tests, as they all assess aspects
of upper limb functioning. Though, a hierarchy in strength of
the linear relationship between the AMSQ and the different per-
formance measures was expected (hypotheses 9–12), i.e., the
ARAT reflects the same construct as the AMSQ, i.e., “hand/arm
functioning”, and therefore the strongest correlations coefficient
was expected. The 9-HPT, CRT and JAMAR hand strength dyna-
mometer measure narrower constructs compared to the con-
struct measured by the AMSQ, and therefore, lower correlation
coefficients were expected. In addition, one hypothesis regard-
ing expected differences in AMSQ mean sum scores in patients
with spasm and patients without spasm was defined (hypoth-
esis 13).
Spearman’s rho correlations were used for assessing all
hypothesized relations between the AMSQ and PROMs and per-
formance-based measures because scores were non-normally dis-
tributed. Correlation was considered as low <0.30; moderate
0.30–0.59; and high 0.60.[38] Group comparison (patients with
spasm versus patients without spasm) was made by a
Mann–Whitney U Test with a p cutoff value of 0.05.
Reliability
To investigate test–retest reliability of the AMSQ, we calculated
one-way ICC for the whole sample due to an incomplete
design [39] (Reliability question 1). The questionnaires were
administered online, on paper, or as an interview. Mode of self-
administration could vary between baseline and retest measure-
ment (i.e., a patient filled out the baseline questionnaire on
paper at the VUmc, and completed the retest online at home).
For patients at NU baseline AMSQ was administered by two
researchers (L.v.L. or L.M.), and follow-up administration was per-
formed by one of the eight physiotherapists following a time
interval of two to four weeks after initial assessment. In addition,
we investigated whether there was a systematic difference
between two measurements due to differences in mode of
administration (Reliability question 2), and whether there was a
systematic difference between two measurements due to
different observers (Reliability question 3). These two questions
were investigated by calculating ICC two-way ANOVA
random effect models for agreement for patients who completed
baseline and retest questionnaires in different ways of administra-
tion (i.e., paper at baseline and online at follow-up), and for
patients who were interviewed. An ICC value of 0.70, in a sample
of 50 patients was recommended as a minimum standard for
reliability.[40]
Measurement error
The measurement error was determined by calculating the stand-
ard error of measurement (SEM),[41] i.e., the square root of the
error variance from the ICC formula. In addition, measurement
error was expressed as smallest detectable change (SDC). The SDC
represents the minimal change that a patients must show on the
scale to ensure (with 95% confidence) that the observed change
is real and not just measurement error. The SDC was calculated at
a 95% confidence interval by multiplying the SEM by 1.96 and by
the square root of 2.[30] All statistical analyses were performed
using the Statistical Package for Social Science (SPSS) version 20.0
(Chicago, IL).
Results
Patient characteristics and response rate
Patient characteristics are presented in Table 2. In total 112
patients with MS participated, of which 77 patients were
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recruited at the VUmc and 35 patients at NU. All subjects from
NU were residential. Sum scores on the AMSQ were only calcu-
lated for patients who completed all 31 items (94%). Five
patients had one missing item and two patients had two or
three missing items. The total of missing items of the
AMSQ was less than 1%. Mean sum score of the AMSQ was
27.8 (SD ¼ 31.8) and the median was 12.9 (range 0–100). For
the validity analyses we used the scores of the 105 patients
with complete cases on the AMSQ. With regard to the fol-
low-up measurement, 14 of the 77 patients that used self-
administration did not complete the follow-up questionnaire
(response rate of 82%), and four patients did not fully complete
the AMSQ. All 35 patients who were interviewed completed the
follow-up measurement, but three patients had missing items
on the AMSQ. Taken together, 91 patients were eligible for reli-
ability analyses.
Table 1. Specific hypotheses and correlation coefficients of the AMSQ with other measurement instruments (N¼ 105).
Hypothesis Confirmed yes/no Result (r)
PROMs
1 A high correlation was expected between the AMSQ and GNDS upper limb disability domain,
because they measure the same construct based on the framework of the ICF.
Yes 0.84
2 A lower correlation was expected between the AMSQ and the total sum score of the GNDS,
as compared with the correlation between the AMSQ and the GNDS upper limb disability
domain.
Yes 0.69 vs 0.84
3 A moderate correlation between the AMSQ and MSIS-29 physical subscale was expected,
because the MSIS-29 physical subscale measures physical impact of MS in daily life, and is
not specifically focusing on hand and arm functioning.
No 0.77a
4 A higher correlation between the AMSQ and MSIS-29 physical subscale was expected as
compared with the correlation between the AMSQ and RAND-36 physical functioning
subscale, because the MSIS-29 is a MS specific instrument and the RAND-36 is not.
No 0.77 vs 0.81b
5 A higher correlation between the AMSQ and the physical functioning subscale of the
RAND-36 was expected as compared with RAND-36 physical component summary score.
Yes 0.81 vs 0.61b
6 A higher correlation between the AMSQ and the MSIP-ADL subscale was expected as com-
pared with the MSIS-29 physical subscale, because limitations in upper extremity function-
ing strongly influence ADL and the AMSQ focuses on functioning of ADL.
Yes 0.80c vs 0.77
7 Low correlations were expected between the AMSQ and the MSIS-29 psychological subscale,
because they measure non-similar constructs.
Yes 0.17a
8 Low correlations were expected between the AMSQ and RAND-36 mental component
summary score (MCS), because they measure non-similar constructs.
Yes 0.02b
Performance testsd
9 High correlations were expected between the AMSQ and ARA test, because the ARAT is
developed for upper extremity motor function including both grip and pinch, and fine and
gross arm movements.
Yes 0.65e
10 Somewhat lower correlations were expected between the AMSQ and 9-HPT, because in
contrast to the ARAT, the 9HPT focuses more specifically on hand function and finger
dexterity while the AMSQ assesses the whole upper extremity.
No 0.77f vs 0.65
11 It was expected that the AMSQ will show somewhat lower correlations with the CRT as
compared with the correlation between the AMSQ and 9-HPT, because the CRT focuses
even more specifically on the hand and finger dexterity as compared with the 9-HPT.
No 0.77g vs 0.77
12 It was expected that the AMSQ will show lower correlations with the JAMAR hand strength
dynamometer, as compared with the correlations between the AMSQ and the CRT,
because the AMSQ does not specifically measures hand strength.
Yes 0.67 vs 0.77
13 It was expected that patients with spasticity (MAS 1) score statistically significantly higher
on the AMSQ as compared with patients without spasticity (MAS ¼0), because spasticity is
a causative for activity limitations due to impairments of the arm and hand.
Yes p< 0.05
Low¼ correlation<0.30; Moderate¼ correlation 0.30–0.59; High¼ correlation0.60.
r: Spearman’s rho correlation; PROMs: Patient Reported Outcome Measures; AMSQ: Arm function in Multiple Sclerosis Questionnaire; GNDS: Guy’s Neurological
Disability Scale; Rand-36: The 36 item short form health survey; PF: physical functioning; MSIS-29: Multiple Sclerosis Impact Scale; MSIP-ADL: The Multiple Sclerosis
Impact Profile-Activities of Daily Living; 9HPT: Nine Hole Peg Test; CRT: Coin Rotation Task; ARAT: Action Research Arm Test; JAMAR: dynamometer for measuring
hand strength.
aSix items were imputed.
bN¼ 95; 10 patients did not fill in the RAND-36. Nine items were imputed.
cOne item was imputed.
dAveraged performance test scores for N¼ 105, dominant/non-dominant hand scores for N¼ 104 due to 1 missing item on hand dominance.
eN¼ 91; 14 patients had no scores, because they could not perform the test due to practical problems.
f13 and 16 patients had a value of 300 seconds on dominant and non-dominant hand, respectively, because they could not perform the test due to hand and arm
impairments.
g26 and 28 patients had a value of 300 seconds on dominant and non-dominant hand, respectively, because they could not perform the test due to hand and arm
impairments.
Table 2. Patient characteristics (N¼ 112).
Age (years) Mean (SD) 47.6 (11.6)
min-max 20–72
Gender female 55.4%
Recruitment method Active application at VUmc and from websites 11.6%
Regular patient visits at VUmc 48.2%
Ongoing research projects at VUmc 8.9%
Inpatient recruitment at NU 31.3%
Disease duration median 13
(years) min-max 1–49
Self. Adm. EDSS mean (SD) 5.4 (2.7)
min-max 0–9
MS type Relapsing Remitting (RR) 50.5%
Secondary Progressive (SP) 21.1%
Primary Progressive (PP) 11.9%
CIS and unknown 16.5%
SD: standard deviation, min: minimum; max: maximum; Self. Adm.: self-adminis-
tered; EDSS: Expanded Disability Status Scale; CIS: Clinically Isolated Syndrome.
Missing values were found in the variables age (N¼ 1), disease duration (N¼ 8)
and MS type (N¼ 3).
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Construct validity
The correlation coefficients between the AMSQ mean sum score
and the mean values of other measures are presented in Table 1.
In summary, 9 out of the 13 predicted hypotheses were confirmed
(69.2%). As expected, moderate to high correlation coefficients
were found between the AMSQ and (sub) scales measuring phys-
ical functioning (hypotheses 1–6) and low correlation coefficients
were found between the AMSQ and (sub) scales measuring non-
similar constructs (hypotheses 7 and 8). The correlations between
the AMSQ and all performance-based hand and arm function tests
(hypotheses 9–12) were moderate to high, as expected. Although
the hierarchical order of the three comparator tests was not as
expected, i.e., the ARAT showed a lower correlation coefficient
with the AMSQ when compared with the observed coefficients of
the other performance tests. In line with expectations, we found a
significant difference between patients with spasticity (N¼ 30) ver-
sus no spasticity (N¼ 71) on the AMSQ sum score (U¼ 557.5;
p< 0.05).
Reliability
Five patients reported “much better” or “much worse” on the GPE
and were excluded for analyses. Of the remaining sample (N¼ 86),
55 patients self-administered the questionnaires and 31 patients
were interviewed at baseline and follow up. Of the patients who
self-administered the questionnaires, 43 patients used different
modes of administration for baseline and follow-up measurement
(i.e., paper at baseline and online at follow-up), and 12 patients
used the same method (i.e., both administrations were online).
None of the patients self-administered the questionnaire twice on
paper. The results addressing the three research questions con-
cerning reliability are presented in Table 3.
Discussion
The AMSQ is a newly developed tool to measure activity limita-
tions due to hand and arm functioning in patients with MS. The
first quality assessment by IRT methods showed good results, and
in this second study we evaluated the psychometric properties of
the AMSQ using traditional CTT methods. We assessed construct
validity, reliability and measurement error.
The validity analysis showed satisfying results for construct val-
idity of the AMSQ (confirmed hypotheses 69.2%). As expected, the
AMSQ showed moderate to strong linear relationships with
PROMs measuring similar constructs and the performance-
based tests. Hypotheses 3, 4, 10 and 11 were not confirmed.
Surprisingly, a stronger relationship was found between the AMSQ
and RAND-36 physical subscale (which is developed for the gen-
eral population) when compared with the relationship between
the AMSQ and MSIS-29 physical subscale, which similar to the
AMSQ, was specifically developed for patients with MS (i.e.,
hypotheses 3 and 4). The items of the AMSQ and RAND-36 all ask
only about limitations in performing activities, while 7 out of 20
items of the MSIS-29 physical subscale ask about limitations due
to specific causes, such as balance, clumsy, stiffness, tremor, and
spasms. It is likely that therefore the construct measured by the
MSIS-29 is different from the constructs as measured by the
AMSQ and the RAND-36. Furthermore, the correlations between
the AMSQ and the ARAT in our study were not as expected (i.e.,
hypotheses 10 and 11). Originally, the ARAT was developed to
assess upper extremity function following cortical injury. Although
the ARAT was shown valid for measuring upper extremity func-
tioning patients with MS,[42] the test seemed not suitable for
measuring hand and arm functioning in the present study sample.
One explanation might be that patients scored mostly the best
possible score (i.e., 66% had an average score>55) despite claim-
ing dexterous difficulties, as well as that in more severely disabled
patients (EDSS 8) the test could not be administered due to
practical problems (22%), e.g., wheelchair dependent patients
could not reach all parts of the ARAT box. Similar results and
remarks regarding validity and ceiling effects on the ARAT in MS
patients have been reported in other studies.
The high-reliability coefficients and low measurement error
support the value of the AMSQ in clinical trials with relatively
small sample sizes, regardless of different modes of administration
both between and within patients. The reliability coefficient deter-
mined on different modes of administration provided good sup-
port for the equivalence of scores from online, paper or interview
administration. This corresponds to findings of our previous
study,[20] which showed no DIF on any of the 31 items of the
AMSQ for mode of administration. In clinical practice a SEM of
(approximately) 6 points means that when a patient gets a score
of for example 28 points, in reality the score will lie somewhere
between 22 points and 34 points. The SDC was 17.5 points (on a
scale of 0 to 100). This means that when an individual patient is
measured over time, a change score of at least 18 points needs to
occur in order to conclude that in reality (with a 95% certainty) a
change beyond measurement error has occurred in an individual
patient. The SDC for self-report was smaller than the SDC for
interview (15.6 vs. 20.0). This could be taken into account when
using the instrument, for example in a randomized controlled trial.
It could also be possible that the measurement error for patients
who have lower functioning level is larger, which were the
patients that were interviewed. For the interpretation of change
scores of PROMs, results on both the SDC and the minimal
important change are needed (MIC; i.e., the smallest change in
score which patients perceive as important). An instrument is use-
ful in clinical practice if the SDC is smaller than the minimal
important change. A next step therefore is to determine whether
the smallest detectable change is sufficiently small, i.e., smaller
than the minimal important change. Note that when using the
Table 3. Reliability question numbers and reliability of the AMSQ.
Method of
administration
nr Baseline Re-test N ICC method ICC (95%CI) r2p r
2
o r
2
residual SEM (% of scale range) SDC d
-
1 Paper
Interview
Online
Online
Interview
Online
86 One-way ANOVA 0.96 (0.94–0.97) 955.23 NA 38.97 6.3 (6.3%) 17.5 0.20
2 Paper Online 43 Two-way ANOVA 0.88 (0.79–0.93) 242.36 0.97 31.34 5.6 (5.6%) 15.6 1.85
3 Interview Interview 31 Two-way ANOVA 0.94 (0.88–0.97) 796.98 0.00 51.62 7.2 (7.2%) 20.0 1.02
ICC: intraclass correlation coefficient; CI: confidence interval; SEM: standard error of measurement; SDC: smallest detectable change; NA: not applicable; r2p the
variance of the patients (i.e., the systematic differences between the “true” scores of the patients); r2o the variance due to systematic differences between the
measurements/observers; r2residual the random error variance; d
-: the systematic difference.
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instrument in a study to measure change in a group of patients,
the measurement error of the mean change score is much lower
(SDC/n).[41]
Since the AMSQ is developed using IRT methods, trait level (h)
scores can be obtained. The considerable advantage of theta
scores is their ability to handle missing data. The analyses were
repeated using trait level (h) scores. The correlation between the
sum scores and theta scores was 0.92. Similar results were
obtained for construct validity as well as for reliability analyses
(data not shown).
Study strengths and limitations
According to international guidelines, a minimum of 50 patients is
considered adequate for assessing measurement properties.[43]
We included 102 patients for validity and 86 patients for reliability
analyses and thus largely met this criterion. Furthermore, we had
little missing data on the AMSQ and all other questionnaires.
Therefore, we do not expect that the missing data has led to bias.
Some limitations need to be addressed regarding the present
study. Patients self-indicated their diagnosis of MS. Because of
ethical and regulatory restrictions, the diagnosis of MS was not
confirmed by accessing medical records. This limitation might limit
the generalizability of the results. However, given the study sam-
ple largely consisted of patients that either visited the academic
hospital (VUmc) for treatment or were admitted to a residential
care facility that is specialized in care for MS patients (NU), the
vast majority of patients were known to us with the right diagno-
sis (MS). We are therefore confident the self-indicated diagnosis
was valid and that this has not led to bias. Regarding the per-
formance-based tests, missing data were mostly obtained due to
practical problems using the ARAT, which could have led to bias.
Furthermore, we averaged the scores of the dominant and non-
dominant hands on the performance-based tests. This could have
introduced bias on the representativeness of the found correla-
tions. However, the outcome did not change using only scores for
the dominant and non-dominant hand, respectively (data not
shown). Another limitation was that we had loss to follow-up for
the second questionnaire (13%). However, the patient characteris-
tics of non-responders were not different as compared with res-
ponders, dismissing that this may have caused different results.
Furthermore, we used a GPE to define stable patients for reliability
assessment. Such a measure has several limitations,[44–46] includ-
ing questionable validity, recall bias and influence of current sta-
tus. Although we cannot rule out recall bias, we believe clinically
important changes were unlikely to occur in two to four weeks.
Moreover, the negligible systematic differences that were found
might be an indication that biological variance or recall bias had
no influence. Unfortunately one item of the MSIP was inadvert-
ently not included in this study. This might have led to bias
regarding the correlation coefficient for the relation between the
scores on the AMSQ and MSIP.
Conclusion and practical implication
The results of this study show satisfying results for validity and
excellent results for reliability in a sample of Dutch patients with
MS. This second evaluation of measurement properties support
that the AMSQ is an adequate scale for measuring arm and hand
functioning in patients with MS in clinical research. Further
research will determine whether the same results apply to transla-
tions into other languages. An English version is currently under
investigation in an Irish population,[47] and another study is
ongoing for translating and validating the German version of the
AMSQ.[48]
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Appendix 1
Arm Function in Multiple Sclerosis Questionnaire (AMSQ)
Copyright of the AMSQ is held by the MS Center Amsterdam of
VUmc. For translations in other languages please contact the cor-
responding author.
Please note that the AMSQ was developed in Dutch, and after-
wards translated into English. All analyses described in this article
are based on the Dutch 31-item version of the AMSQ.
Please read the instructions below carefully before starting on
the questions
 All questions are about the past 2 weeks.
 For each question, please circle one number that best
describes your situation.
 In case you never perform an activity:
 Choose ‘‘no longer able (to)’’ if you no longer per-
form the activity because of limitations in the use
of your arm.
 When you are asked about an activity you never
perform (or performed), please try to imagine
whether you are limited in your ability to perform
the activity.
 Some questions are about activities that you can perform
with one hand. When answering these questions, please
choose the arm with which you.
 Always performed this activity (before you had any
complaints).
If you use aids or adapted equipment to perform an
activity, please try to imagine how you would do without
these aids.
Nr. During the past 2 weeks, to what extent has MS… Not at all A little Moderately Quite a bit Extremely
No longer
able to
1 Limited your ability to write down a short sentence with a pen? 1 2 3 4 5 6
2 Limited your ability to grasp small objects, for example a key or a ballpoint pen? 1 2 3 4 5 6
3 Limited your ability to put on a coat? 1 2 3 4 5 6
4 Limited your ability to tie shoelaces? 1 2 3 4 5 6
5 Limited your ability to hold a full plate? 1 2 3 4 5 6
6 Limited your ability to pour from a bottle into a glass? 1 2 3 4 5 6
7 Limited your ability to turn the pages of a book? 1 2 3 4 5 6
8 Limited your ability to use a mouse of a computer? 1 2 3 4 5 6
9 Limited your ability to use a pen or pencil? 1 2 3 4 5 6
10 Limited your ability to turn a key in a lock? 1 2 3 4 5 6
11 Limited your ability to cut off a piece of paper with a pair of scissors? 1 2 3 4 5 6
12 Limited your ability to fasten a seatbelt in a car? 1 2 3 4 5 6
13 Limited your ability to fasten buttons? 1 2 3 4 5 6
14 Limited your ability to unbutton your shirt? 1 2 3 4 5 6
15 Limited your ability to take off a sweater or T-shirt? 1 2 3 4 5 6
16 Limited your ability to pick up coins from the table? 1 2 3 4 5 6
17 Limited your ability to use a keyboard? 1 2 3 4 5 6
18 Limited your ability to zip up a coat? 1 2 3 4 5 6
19 Limited your ability to carry a shopping bag? 1 2 3 4 5 6
20 Limited your ability to wash your hands? 1 2 3 4 5 6
21 Limited your ability to cut something with a knife? 1 2 3 4 5 6
22 Limited your ability to pierce food with a fork? 1 2 3 4 5 6
23 Limited your ability to dry off your body? 1 2 3 4 5 6
24 Limited your ability to open a bottle that has a screw cap? 1 2 3 4 5 6
25 Limited your ability to open a bottle of soft drink? 1 2 3 4 5 6
26 Limited your ability to wash the back of your shoulder? 1 2 3 4 5 6
27 Limited your ability to wash your hair? 1 2 3 4 5 6
28 Limited your ability to open a bag of crisps? 1 2 3 4 5 6
29 Limited your ability to bring a full glass or cup to your mouth? 1 2 3 4 5 6
30 Limited your ability to put toothpaste on a toothbrush? 1 2 3 4 5 6
31 Limited your ability to tuck a T-shirt/shirt in the back of your trousers using your hand? 1 2 3 4 5 6
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